Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) EPS (Basic) (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed EPS (Basic) for 13 consecutive years, with -$0.15 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Basic) rose 37.5% to -$0.15 in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.09, a 14.84% increase, with the full-year FY2025 number at -$1.09, up 14.84% from a year prior.
  • EPS (Basic) was -$0.15 for Q4 2025 at Iovance Biotherapeutics, up from -$0.25 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of -$0.15 in Q4 2025 to a low of -$474.55 in Q2 2023.
  • A 3-year average of -$39.89 and a median of -$0.35 in 2024 define the central range for EPS (Basic).
  • Peak YoY movement for EPS (Basic): soared 99.93% in 2024, then increased 2.94% in 2025.
  • Iovance Biotherapeutics' EPS (Basic) stood at -$0.81 in 2023, then skyrocketed by 70.37% to -$0.24 in 2024, then surged by 37.5% to -$0.15 in 2025.
  • Per Business Quant, the three most recent readings for IOVA's EPS (Basic) are -$0.15 (Q4 2025), -$0.25 (Q3 2025), and -$0.33 (Q2 2025).